What is the value of oncology medicines?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).BMC health services research · 2015
   Pooled it
2. Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.PharmacoEconomics - open · 2018
   Review
3. "Just caring": can we afford the ethical and economic costs of circumventing cancer drug resistance?Journal of personalized medicine · 2013
   Article
4. Translational research and the evolving landscape for biomedical innovation.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2012
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as